We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 69,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
We're tracking Novo Nordisk's market expansion
315 signals in the last 90 days.
How Novo Nordisk's international expansion compares to its competitors
Novo NordiskYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Novo NordiskYou | 0 | 0 | — | 0 | 0 |
Senior IT/OT Solution Architect - API Expansion
View postingKalundborg, Region Zealand, Denmark · today
Representative, HR
View postingBloomington, IN · 4d ago
Study Start Up Specialist
View postingGatwick, England, United Kingdom · 4d ago
Talk to a doctor
Ended
Talk to a doctor
Ended
Talk to a doctor
EndedBrazilian pharmaceutical EMS will launch a national version of semaglutide on June 15, priced at R$452 per pen, 30% cheaper than imported alternatives like Ozempic, making obesity treatment more accessible.
Caliway Biopharma presented CBL-514 animal study data at ADA 2026, showing combination with GLP-1/RA drugs reduces weight rebound by 2.7 times and liver fat by 106.7% versus monotherapy.
Novo Nordisk launches Sogroya (somapacitan) in China, a once-weekly long-acting growth hormone for children aged 2.5+ with growth hormone deficiency, featuring innovative fatty acid technology and zero PEG formulation.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Novo Nordisk's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
